iMQT_020
Based on 1 Customer Validation
iMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS. iMQT_020 induces apoptosis and ferroptosis. iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer, lung cancer, and colon cancer.
For research use only. We do not sell to patients.
- Purity : 99.45%
- CAS No.: 2463893-46-9
- Formula: C14H8ClFN2O3
- Molecular Weight:306.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
iMQT_020 shows the strongest inhibitory effect on mitochondrial glutamine uptake (IC50 = 6.156 μM) at a concentration of 10 μM[1].
iMQT_020 (0-100 μM) directly binds to SLC1A5_var WT protein (Kd = 4.473 μM), but does not bind to FIL/AAA mutants[1].
iMQT_020 (4 μM) significantly reduces the CD signal of the SLC1A5_var WT protein, indicating a structural change[1].
iMQT_020 (10 μM) reduces glutamine-derived TCA cycle metabolites (such as glutamate, αKG, succinic acid, etc.) and downstream products (such as glutathione, proline) in MIA PaCa-2 cells[1].
iMQT_020 (10 μM, 24 h) reduces GSH levels in MIA PaCa-2 cells and increases cellular ROS and mitochondrial ROS[1].
iMQT_020 (10 μM, 24 h) reduces OCR and ECAR in SLC1A5_var WT-overexpressing MIA PaCa-2 cells, but did not affect FIL/AAA mutants[1].
iMQT_020 (10 μM, 24 h) alters mitochondrial morphology in MIA PaCa-2 cells (reducing fragmentation) and decreases mitochondrial membrane potential (reduced TMRE staining)[1].
iMQT_020 (48 h) selectively inhibits the viability of cancer cells (IC50 5-40 μM) without affecting normal cells[1].
iMQT_020 (10 μM, 24 h) upregulates PD-L1 mRNA and protein expression in human PDAC cell lines (such as SU.86.86, SW1990) and mouse carcinoma cell lines (KPC, LLC, MC-38)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
iMQT_020 (75 mg/kg, i.p., once daily for 35 days) inhibits tumor growth in a mouse orthotopic transplantation model of MIA PaCa-2 cells[1].
iMQT_020 (75 mg/kg, i.p., once daily for 35 days) inhibits the growth of xenografted tumors of NCI-H1299 human lung cancer cells and COLO 205 human colon cancer cells in mice[1].
iMQT_020 (25 mg/kg, i.p., once daily for 21 days), when used in combination with an anti-PD-L1 antibody (aPD-L1), synergistically inhibits the growth of allogeneic tumors formed from KPC, LLC, or MC-38 cells in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subcutaneous injection of 5.0 × 106 MIA PaCa-2 human pancreatic cancer cells into nude mice was performed to establish a tumor xenograft model[1].
-
Dosage:75 mg/kg
-
Administration:I.p., once daily for 35 days
-
Result:Tumor volume and weight were significantly reduced.
The number of cleaved caspase-3 (apoptosis marker) and 4-HNE (lipid peroxidation marker) positive cells increased, while the number of Cyclin D1 and Ki-67 (proliferation marker) positive cells decreased.
-
Animal Model:Athymic NCr-nu/nu nude mice were injected orally into the pancreas with 5.0 × 105 luciferase-labeled MIA PaCa-2 cells to form an in situ tumor model that simulates the pancreatic cancer microenvironment[1].
-
Dosage:75 mg/kg
-
Administration:I.p., once daily for 35 days
-
Result:Tumor growth is inhibited, and tumor weight is reduced.
-
Animal Model:Athymic NCr-nu/nu nude mice were subcutaneously injected with NCI-H1299 human lung cancer cells or COLO 205 human colon cancer cells to form a xenograft model[1].
-
Dosage:75 mg/kg
-
Administration:I.p., once daily for 35 days
-
Result:The tumor volume and weight were significantly reduced, and immunohistochemistry showed increased apoptosis and ferroptosis markers.
-
Animal Model:C57BL/6N mice were subcutaneously injected with KPC (mouse pancreatic cancer cells), LLC (Lewis lung cancer cells), or MC-38 (mouse colon cancer cells) to establish an allogeneic transplantation model[1].
-
Dosage:25 mg/kg
-
Administration:I.p., once daily for 21 days
-
Result:Combined with aPD-L1, it significantly reduced tumor volume and weight.
PD-L1 expression was increased in tumor tissue, along with increased CD8+ T cell infiltration, elevated IFN-γ and Granzyme B positive cells, while PD-1+ T cells, Treg cells, MDSCs, and TAMs were decreased.
Ki-67 (proliferation) was decreased, and cleaved caspase-3 (apoptosis) was increased.
Chemical Information
-
CAS No. 2463893-46-9
-
Appearance Solid
-
Molecular Weight 306.68
-
Formula C14H8ClFN2O3
-
Color White to off-white
-
SMILES
ClC1=C(O)C=C(F)C(C2=CC=C(NC(NC3=O)=O)C3=C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (326.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2607 mL | 16.3036 mL | 32.6073 mL | 81.5182 mL |
| 5 mM | 0.6521 mL | 3.2607 mL | 6.5215 mL | 16.3036 mL | |
| 10 mM | 0.3261 mL | 1.6304 mL | 3.2607 mL | 8.1518 mL | |
| 15 mM | 0.2174 mL | 1.0869 mL | 2.1738 mL | 5.4345 mL | |
| 20 mM | 0.1630 mL | 0.8152 mL | 1.6304 mL | 4.0759 mL | |
| 25 mM | 0.1304 mL | 0.6521 mL | 1.3043 mL | 3.2607 mL | |
| 30 mM | 0.1087 mL | 0.5435 mL | 1.0869 mL | 2.7173 mL | |
| 40 mM | 0.0815 mL | 0.4076 mL | 0.8152 mL | 2.0380 mL | |
| 50 mM | 0.0652 mL | 0.3261 mL | 0.6521 mL | 1.6304 mL | |
| 60 mM | 0.0543 mL | 0.2717 mL | 0.5435 mL | 1.3586 mL | |
| 80 mM | 0.0408 mL | 0.2038 mL | 0.4076 mL | 1.0190 mL | |
| 100 mM | 0.0326 mL | 0.1630 mL | 0.3261 mL | 0.8152 mL |
iMQT_020 Related Classifications
HY-179557 Related Classifications
Powered by Bioz